Deep Vein Thrombosis

Deep Vein Thrombosis

The global deep vein thrombosis (DVT) market relates to the diagnosis, therapy, and prevention of blood clots located in deep veins predominantly in lower limbs, which if left unattended may cause a life-threatening disease known as pulmonary embolism. The market is therefore motivated by these factors including increasing incidences of DVT especially among the aging populace, rising awareness of the condition, improvement in diagnostic tools and treatment options, and increasing risk factors which include obesity, less active lifestyles, and other conditions that are known to cause the condition. Also, the increasing number of healthcare facilities across emerging nations and the incorporation of the latest anticoagulant drugs sustain market growth. Currently, healthcare organizations are striving to address DVT to lessen the risk of adversative events within the global market, enhancement, especially in research and development to benefit patients.

The market for deep vein thrombosis market is set to exhibit a growth rate of about 8%. This is mainly due to the rise in surgical procedures, especially orthopedic surgeries, which increases the need for DVT prophylaxis and treatment. Also, advancements in imaging and diagnostic tools and growing investment in R&D for the treatment of DVT will further boost the market growth. For instance, in 2021, Boston Scientific, a leading medical device company, announced it would acquire Preventice Solutions, Inc., a mobile cardiac health solutions developer, and remote monitoring services, for up to USD 1.2 billion.

• Based on the drug class, the market is segmented into anticoagulants, heparin, and others. The anticoagulants category is expected to have the largest market share of the deep vein thrombosis market by offering essential therapeutic options for both acute treatment and long-term management of DVT. DOACs have removed DVT treatment from traditional therapeutics such as warfarin and made it safer and more convenient. New point-of-care oral anticoagulants, including apixaban, rivaroxaban, dabigatran, and edoxaban have certain characteristics and are distinguished from warfarin by a quick onset of action, more favorable pharmacokinetics, limited restrictions in terms of diet and relatively low requirements in terms of monitoring. It has as a result enhanced patient compliance and improved results and therefore the market size has spread. Further, the existing research and innovation conducted in this category are aimed at increasing the effectiveness, safety measures, and patient compliance to fuel the growth of the DVT market as such therapies spread all over the global market.
• Based on the treatment, the market is segmented into surgery, drugs, and others. Among these, the drugs category is expected to have the largest market share of the deep vein thrombosis market due to the progression in pharmaceutical care, especially among some types of drugs, such as anticoagulants warfarin and direct oral anticoagulants. The market is also growing constantly because current research has been directed at creating not only safer but also more effective anticoagulants. Also, biosimilar, and generic availability contribute to the affordability and accessibility of these treatment programs. Also, preventive medication for high-risk patients, including the major surgery ones, boosts demand for this medication type, and, thus, will stimulate global market growth.
• Based on the end-user, the market is segmented into hospitals, specialty clinics, academic & CROs, and others. Among these, the hospital category is expected to lead the market share of the deep vein thrombosis market during the forecast period. Primary care centers and hospitals are often the first point of contact for patients presenting with DVT symptoms. The adoption of advanced diagnostic tools and imaging technologies in hospitals facilitates early and accurate diagnosis, which is crucial for effective management and improved patient outcomes. Moreover, hospitals are central to implementing prophylactic measures, especially for patients undergoing surgeries or those with prolonged immobility, significantly contributing to the prevention and management of DVT.
• For a better understanding of the market adoption of deep vein thrombosis treatment, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The market environment of North America Deep Vein Thrombosis (DVT) is highly advanced in terms of healthcare facilities, awareness, and strong R&D. The incidence of risks like obesity, sedentary lifestyle, and aging population across the region presents a large patient pool for generating overall business. The diagnostic development includes the improvement of imaging techniques and the identification of new biomarkers which contribute to better diagnosis and powerful treatment. Additionally, the market entry of strong strategic players focusing on new therapeutic approaches, including novel oral anticoagulants and less invasive procedures, advances the market further. Increased government support for the coverage of healthcare and the education of patients on how to prevent and manage DVT are other prominent roles that help in the determination of the North American market for DVT.
• Some of the major players operating in the market include Medtronic, Aspen Holdings, Novartis AG, Mylan N.V., GLENMARK PHARMACEUTICALS LTD., Hikma Pharmaceuticals PLC, Bristol-Myers Squibb Company, GL Pharma, COBAPHARMA, Boehringer Ingelheim International GmbH.